Europe
Pharnext SA announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of PXT3003 for the treatment of patients with Charcot-Marie-Tooth disease Type 1A.
CARB-X to fund the preclinical development and Phase I clinical trial of a novel OMPTA candidate.
Paras Biopharmaceuticals Finland Oy announced the achievement of a major milestone – the successful development of biologically active Romiplostim production technology.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.
Evonik has completed the conceptual and basic engineering phase for building its new polyamide 12 (PA12) production complex on schedule by the end of the past year and has now entered the project implementation phase.
IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party institutions such as clinicaltrials.gov, and syndicated and analyst reports to make their list.
Shares of Paris-based GenSight plunged nearly 19 percent Monday after the company announced that its gene therapy for Leber hereditary optic neuropathy (LHON) failed to show a significant effect in patients at 48 weeks.
Sirion Biotech International threw a Bavarian-themed grand opening party at the Forsythe Institute on Feb. 1. The new headquarters are in Cambridge, Mass and currently have five employees.
Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.
Almost three months to the day after an FDA advisory committee overwhelmingly rejected Alkermes’ major depressive disorder treatment, ALKS-5461, the company received word that the regulatory agency will not approve the medication.
PRESS RELEASES